Cosmo Intelligent Medical Devices’ Post

Cosmo Pharmaceuticals Reports Stellar Half-Year 2024 Results: I am delighted to share that Cosmo Pharmaceuticals has delivered outstanding half-year results for 2024. Our commitment to innovation and excellence continues to drive remarkable achievements. Here are some key highlights: Financial Performance: - **Revenue:** Reached an impressive €136.2 million, reflecting the strong market demand for our advanced pharmaceutical solutions. - **EBITDA:** Achieved a robust €94.2 million, underscoring our operational efficiency. - **Operating Profit:** Recorded at €87.0 million, showcasing our profitability. - **Net Cash Inflow:** Generated a significant €99.2 million from operating activities. - **Dividend:** Paid a €2.00 per share dividend for FY2023, rewarding our shareholders. Health Tech: - **GI Genius™ Expansion:** Our AI-enhanced endoscopy system continues to grow, with the new ColonPRO™ version approved by the FDA in January. This software incorporates an enhanced algorithm, significantly improving detection capabilities and automating physician workflows. **Dermatology Success:** - **Winlevi® Dominance:** Continues to be the #1 prescribed topical acne product in the U.S. The global expansion is on track with successful launches in Canada and Australia. Submissions for approval are ongoing in 14 additional countries, promising further growth. **Gastroenterology Growth:** - **Increased Shipments:** Our GI products have seen a surge in shipments to partners, reflecting our expanding market presence. **CDMO Growth:** - **Revenue Increase:** Our contract development and manufacturing organization (CDMO) division grew by 9.3%, driven by higher orders from existing customers. **Pipeline & Regulatory Highlights:** - **New Submissions:** GI Genius™ module 300 powered by Nvidia IGX has been submitted to the FDA for clearance. - **Clinical Trials:** Progressing well with key trials, including the Androgenetic Alopecia phase III trial and Distal Ulcerative Colitis phase II study. - **Global Approvals:** Lumeblue® New Drug Application approved in China, with our partner CMS preparing for the launch. These achievements underscore our relentless pursuit of quality and innovation, driving forward our mission to enhance healthcare outcomes worldwide. I am immensely proud of our team’s dedication and excited about the future prospects. Thank you to our incredible team, partners, and shareholders for your unwavering support. Together, we are shaping a brighter future at Cosmo Pharmaceuticals! https://lnkd.in/eFy54vUJ Cosmo Pharmaceuticals Andrea Cherubini Nhan Ngo Dinh Hazel Winchester #EarningsResults #Pharmaceuticals #Innovation #Healthcare #Growth #CosmoPharmaceuticals #TeamSuccess